Kashiv Biosciences has reported that a trial of its 125mg/mL pre-filled syringe injection, KSHB002, has achieved its primary ...

Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept biosimilar ...

Although Dr Reddy's Laboratories' Q3 earnings slightly exceeded analysts' expectations, the main point of concern was the ...

Shares of Dr Reddy's Laboratories Ltd tumbled more than 6.65 per cent to Rs 1,203.60 on Friday, with its total market ...

Dr Reddy's shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay ...

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Indian Car of the Year 2025 - Mahindra Thar Roxx Indian Motorcycle of the Year 2025 - Aprilia RS 457 The Indian Car of the Year (ICOTY) and Indian Motorcycle of the Year (IMOTY) awards, pr... "Lorem ...

Among the launches are Semaglutide in Canada, with a market size of $2 billion, and Abatacept in the US, with a market size of $2.8 billion. Semaglutide, a diabetic injection, goes off-patent in ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the impact of Revlimid’s patent expiry in 2026. The brokerage set a target ...

Key launches, including Semaglutide in Canada and the Abatacept biosimilar in the US, are expected to offset revenue losses from Revlimid’s patent expiration. However, the brokerage noted risks such ...